ClinicalTrials.gg
Status unknownNCT05168007Updated Dec 22, 2021

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

A Phase 3 interventional study of WID-RGC20(Cariprazine) 3mg/day and WID-RGC20(Cariprazine) 6mg/day in Schizophrenia, sponsored by Whanin Pharmaceutical Company. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-12-22.

Sponsored by Whanin Pharmaceutical Company · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Planned enrollment
9th of 23
342 · median 129
Started
2021
the only one that year
Phase 3
8 of 23
1 open now
Registered
17th of 23
by date
Lead sponsor
1 of 23
Whanin Pharmaceutical Company

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 9th largest by planned enrollment, is the only one that started in 2021, is one of 8 in phase 3, and was the 17th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic Episode of Schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 19 ≤ age \< 65 years
  • At least 1 year of schizophrenia diagnosed according to criteria(295.90)
  • At least 1 psychotic episode within 1 year
  • Current psychotic episode(acute exacerbation of schizophrenia) within 2 weeks
  • 80 ≤ PANSS total score ≤ 120
  • Rating of at least 4(moderate) on at least 2 of the following 4 PANSS positive symptoms
  • CGI-S score ≥ 4
  • Patients who can be hospitalized during the screening period and at least 3 weeks of the initial double-blind treatment phase

Exclusion criteria

Exclusion Criteria:

  1. Psychiatric Criteria

    • Medical history except schizophrenia specified in protocol
    • First-episode psychosis
    • Treatment-resistant schizophrenia within 2 years
    • Positive result from the blood alcohol concentration(BAC) test or the urine drug screen(UDS)
    • Have suicide risk
  2. Treatment-related Criteria

    • Electroconvulsive therapy(ECT) within 12 weeks or Previous lack of response to ECT
    • Concomitant treatment with 3 or more antipsychotics within 12 weeks
    • Treatment with flunitrazepam or LAI antipsychotics less than 1 cycle or clozapine within 24 weeks
    • Treatment with inducers or potent CYP3A4 inhibitors
    • Treatment with amiodarone or systemic for ≥ 12 weeks within 1 year
    • Required prohibited concomitant medication during the study period
    • Prior participation in any clinical trials of Cariprazine
  3. Other

    • Ophthalmic medical findings or related history(ex. uncontrolled diabetes or hypertension)
    • Abnormal laboratory findings specified in protocol
    • Not suitable for any other reason, as judged by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (estimated)

Study arms

  • Experimental
    Cariprazine 3mg/day

    WID-RGC20(Cariprazine) 3 mg/day

    Drug: WID-RGC20(Cariprazine) 3mg/day

  • Experimental
    Cariprazine 6mg/day

    WID-RGC20(Cariprazine) 6 mg/day

    Drug: WID-RGC20(Cariprazine) 6mg/day

  • Placebo comparator
    Placebo

    Placebo for WID-RGC20(Cariprazine) 3 mg/day or 6mg/day

    Drug: Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day

Interventions

  • DrugWID-RGC20(Cariprazine) 3mg/day

    Drug page: Cariprazine

    The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).

  • DrugWID-RGC20(Cariprazine) 6mg/day

    Drug page: Cariprazine

    The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).

  • DrugPlacebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day

    The placebo comparator is administered during the double-blind treatment period(6 weeks).

06

What researchers measure

Primary outcomes

  1. Positive And Negative Syndrome Scale(PANSS) total score

    Change from baseline in Positive And Negative Syndrome Scale(PANSS) total score at Week 6

    Time frame: at Week 6

Secondary outcomes

  1. Clinical Global Impressions-Severity(CGI-S)

    Change from baseline in Clinical Global Impressions-Severity(CGI-S) at Week 6

    Time frame: at Week 6

Other outcomes

  1. Positive And Negative Syndrome Scale(PANSS) total score

    Change from baseline in Positive And Negative Syndrome Scale(PANSS) total score at Week 1, 2, 3, 4, 5

    Time frame: up to 5 weeks

  2. Clinical Global Impressions-Severity(CGI-S)

    Change from baseline in Clinical Global Impressions-Severity(CGI-S) at Week 1, 2, 3, 4, 5

    Time frame: up to 5 weeks

  3. Clinical Global Impressions-Improvement(CGI-I)

    Clinical Global Impressions-Improvement(CGI-I) at Week 1, 2, 3, 4, 5, 6

    Time frame: up to 6 weeks

  4. Positive And Negative Syndrome Scale(PANSS) positive score

    Change from baseline in Positive And Negative Syndrome Scale(PANSS) positive score by Week 6

    Time frame: up to 6 weeks

  5. Positive And Negative Syndrome Scale(PANSS) negative score

    Change from baseline in Positive And Negative Syndrome Scale(PANSS) negative score by Week 6

    Time frame: up to 6 weeks

  6. Positive And Negative Syndrome Scale(PANSS) responder

    Percentage of subjects with at least 30% reduction in the Positive And Negative Syndrome Scale(PANSS) total score at Week 6 compared with baseline

    Time frame: at Week 6

  7. Adverse event(AE)

    Incidence of Adverse event(AE)s by Week 8

    Time frame: up to 8 weeks

  8. Suicidal ideation and behavior

    Incidence of suicidal ideation and behavior by Week 8

    Time frame: up to 8 weeks

  9. Extrapyramidal Symptoms(EPS)

    Incidence of Extrapyramidal Symptoms(EPS) by Week 6

    Time frame: up to 6 weeks

  10. Laboratory test

    Change from baseline in clinical laboratory tests by Week 6

    Time frame: up to 6 weeks

07

Study locations

1 site
  • Whan In Pharm.
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jul 2023, 19 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 19 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2021
First posted
Dec 22, 2021
StartActual
Nov 19, 2021
Primary completionEst.
Jul 17, 2023
CompletionEst.
Jul 31, 2023
Last update
Dec 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05168007
Lead sponsor
Whanin Pharmaceutical Company
Responsible party
Sponsor
First posted
Dec 22, 2021
Start date
Nov 19, 2021
Primary completion
Jul 17, 2023 (estimated)
Completion
Jul 31, 2023 (estimated)
Last update
Dec 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion